Document is current
Any future updates will be listed below
-
Authors
Mair, Maximilian J.
Maj-Hes, Agnieszka
Nussbaumer-Pröll, Alina
Puhr, Rainer
Christenheit, Agnieszka
Troch, Marlene
Puhr, Hannah C.
Starzer, Angelika M.
Steindl, Ariane
Eberl, Sabine
Haslacher, Helmuth
Perkmann, Thomas
Minichsdorfer, Christoph
Prager, Gerald W.
Lamm, Wolfgang W.
Berghoff, Anna S.
Kiesewetter, Barbara
Zeitlinger, Markus
Preusser, Matthias
Raderer, Markus
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04369365 at ClinicalTrials.govDocuments that mention this clinical trial
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial
https://doi.org/10.1186/s13027-023-00487-x
-
Funding
Funding for this research was provided by:
Medizinische Universität Wien (research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget, research budget)
- License Information
-
More Information
Article History
Received: 14 July 2022
Accepted: 7 February 2023
First Online: 12 February 2023
Declarations
:
: The trial was performed according to local and institutional guidelines, the Declaration of Helsinki with all applicable amendments, and was approved by the local ethics committee of the Medical University of Vienna (approval no. 1332/2020, 1164/2019).
: Maximilian J. Mair has received travel support from Pierre Fabre. Agnieszka Maj-Hes has received honoraria for lectures or advisory board participation from Astellas, BMS, Bayer, MSD, Esai, Sanofi, Roche, Novartis, Pfizer, Janssen, Takeda and GlaxoSmithKline. Hannah Christina Puhr has received travel support from Eli Lilly, MSD, Novartis, Pfizer and Roche and received lecture honoraria from Eli Lilly. Angelika Martina Starzer has received travel support from PharmaMar and honoraria for lectures from AstraZeneca. Anna Sophie Berghoff has received research support from Daiichi Sankyo, Roche, and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. Barbara Kiesewetter declares honoraria for lectures from AAA, Boehringer Ingelheim, Ipsen, Novartis, MSD, Eli Lilly. BK declares Honoraria for advisory boards from Ipsen, Roche. Matthias Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to his institution: Boehringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie. All other authors declare that they have no conflict of interest related to the present study.
